Study Results Indicate Precision Therapies Make Up Approximately Half of FDA-Approved Oncology Drugs
October 19th 2023This finding underlines the need for methods that address multiple genomic alterations and targeted therapies effective in tumors driven by variations in suppressor genes or transcription factors.
Read More
Interchangeability Designation Still Widely Debated, Prescribers Hesitant About Biosimilars
October 19th 2023The FDA is the only authority that can designate a biosimilar as interchangeable with its reference product, which requires that the product has similar clinical results for the same indication.
Read More
Expert: First-Line ADHD Treatment Access for Adults, Children Remains Challenging
October 18th 2023A specialist in adult, child, and adolescent psychiatry discusses the challenges in ADHD treatment for both patients and providers, as well as insights from a recent survey of health care professionals.
Watch